- Home
- KALA vs RDI Comparison
KALA vs RDI Comparison
Compare KALA & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- RDI
- Stock Information
- Founded
- KALA 2009
- RDI 1937
- Country
- KALA United States
- RDI United States
- Employees
- KALA N/A
- RDI N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- KALA Health Care
- RDI Consumer Discretionary
- Exchange
- KALA Nasdaq
- RDI Nasdaq
- Market Cap
- KALA 26.2M
- RDI 30.6M
- IPO Year
- KALA 2017
- RDI N/A
- Fundamental
- Price
- KALA $5.86
- RDI $1.33
- Analyst Decision
- KALA Strong Buy
- RDI Hold
- Analyst Count
- KALA 3
- RDI 1
- Target Price
- KALA $14.00
- RDI $2.40
- AVG Volume (30 Days)
- KALA 118.3K
- RDI 32.9K
- Earning Date
- KALA 08-05-2025
- RDI 08-13-2025
- Dividend Yield
- KALA N/A
- RDI N/A
- EPS Growth
- KALA N/A
- RDI N/A
- EPS
- KALA N/A
- RDI N/A
- Revenue
- KALA N/A
- RDI $205,644,000.00
- Revenue This Year
- KALA N/A
- RDI $7.47
- Revenue Next Year
- KALA N/A
- RDI $13.22
- P/E Ratio
- KALA N/A
- RDI N/A
- Revenue Growth
- KALA N/A
- RDI N/A
- 52 Week Low
- KALA $2.92
- RDI $1.17
- 52 Week High
- KALA $11.20
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- KALA 60.68
- RDI 50.93
- Support Level
- KALA $4.36
- RDI $1.24
- Resistance Level
- KALA $7.00
- RDI $1.31
- Average True Range (ATR)
- KALA 0.71
- RDI 0.06
- MACD
- KALA 0.16
- RDI -0.00
- Stochastic Oscillator
- KALA 63.97
- RDI 62.50
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.